Category: Press Release

2020.09.04

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

2020.08.31

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update

2020.08.17

I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China

2020.08.06

I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020

2020.08.04

China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency

2020.07.28

I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer

2020.07.15

I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million

2020.06.12

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

2020.05.29

I-Mab Announces Upcoming Participation at June Conferences

2020.05.28

I-Mab Reports Interim Results from Part 1 Study for Anti-GM-CSF Antibody TJM2 to Treat COVID-19 Patients with Cytokine Release Syndrome